KAIST Opens the Era of Industrial-Scale Microbial Foods, Proposing Growth Strategies for the Next-Generation Protein Market
The question is no longer whether microbial foods can be made. The question now is who can turn them into an industry first. KAIST researchers have comprehensively analyzed the conditions required for the microbial food industry to succeed across manufacturing, markets, and regulation, and have proposed growth strategies for the next-generation protein industry.
KAIST (President Choongsik Bae) announced on the 31st of July that a research team led by Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering, together with researchers from SilicoBio, a KAIST faculty startup, has comprehensively analyzed the conditions needed for the microbial food industry to succeed in terms of manufacturing, market entry, and regulatory readiness, and has presented an industrialization strategy and roadmap.
This study is significant in that it did not develop a new microorganism or production technology, but instead systematically analyzed the key challenges involved in connecting laboratory-based core technologies to real-world industry. In particular, by presenting an integrated perspective that encompasses manufacturing readiness, market entry strategies, and regulatory responses, the study proposes a direction for developing microbial foods beyond the next-generation protein industry into a future biomanufacturing platform. It is expected to serve as an important milestone for strengthening national biomanufacturing competitiveness and fostering the global sustainable food industry.
The researchers analyzed that competition in the microbial food industry is shifting from productivity at the laboratory level to manufacturing readiness. They identified stable raw material supply and quality control, control and safety assurance of non-model microorganisms, reduction of downstream processing costs, and regulatory compliance for byproduct recycling as key factors that will determine the pace of commercialization. Manufacturing Readiness refers to the level at which a laboratory technology can be reliably produced at industrial scale. Non-model microorganisms are microorganisms with high industrial potential but insufficient accumulated research infrastructure. Downstream processing refers to the processes of separating, purifying, concentrating, and drying target components after fermentation.
The researchers particularly emphasized that future competitiveness will depend less on the excellence of any single technology and more on the ability to build integrated manufacturing platforms. An Integrated Manufacturing Platform refers to a production system that operates the entire process as one connected framework, from strain development and large-scale fermentation to purification, quality control, and product formulation. Even for the same microbial food product, the choice of raw material can affect pretreatment costs and quality variability, while the choice of strain and fermentation process can greatly influence production cost, energy use, and product quality. The researchers therefore concluded that future industrial competitiveness will depend on how quickly companies can build manufacturing platforms that optimize these factors in an integrated way.
On the market side, the researchers also identified the conditions needed for the microbial food industry to succeed. Based on consumer surveys and industry cases, they found that microbial foods cannot spread simply by emphasizing environmental sustainability. Consumers place importance on taste, texture, familiarity, and safety, while food manufacturers value functionality that can be applied to actual products. Companies and investors, meanwhile, consider the predictability of regulatory approval procedures and speed of market entry to be especially important. In other words, the microbial food market has entered an industrial stage where not only technology, but also product development capability and regulatory readiness are evaluated together.
The researchers also argued that microbial foods should not be viewed merely as an alternative protein industry. They suggested that microbial foods have the potential to develop into a core platform for precision fermentation-based functional food ingredients, high-value biomaterials, and circular biomanufacturing. Precision Fermentation is a technology that uses microorganisms to selectively produce specific proteins or functional substances. Circular Biomanufacturing refers to a sustainable manufacturing system that uses byproducts and renewable resources to produce new bio-based products. This means that microbial foods could become not only a future food source, but also a new production system connecting the global food, materials, and biomanufacturing industries.
The industrialization strategy proposed in this study is also closely aligned with the business direction of SilicoBio, which participated in the joint research. Based on the manufacturing readiness strategy presented in the study, SilicoBio is working to build a platform that connects microbial proteins and functional food ingredients to industrial-scale fermentation, scale-up, and product development. Scale-up refers to the process of expanding production from laboratory scale to industrial scale.
Distinguished Professor Sang Yup Lee of KAIST said, “As global competition surrounding synthetic biology and biomanufacturing intensifies, microbial foods are growing into a key industry that will shape national biomanufacturing competitiveness beyond future food.” He added, “Going forward, competitiveness will be determined by how quickly we can build an industrialization ecosystem that connects core technologies to real production and markets.”
A SilicoBio representative said, “Our goal is to connect the industrialization strategy proposed in this study to actual production and commercialization,” adding, “We will build a platform capable of stably producing microbial-based next-generation foods and functional biomaterials.”
This study, with Seok Yeong Jung, a doctoral student in the Department of Chemical and Biomolecular Engineering, as first author and researchers from SilicoBio participating as co-authors, was published on July 17 in the international journal One Earth (Impact Factor 15.3, JCR top 2.07%).
Paper title: Microbial foods as scalable platforms toward a circular protein economy for sustainable nutrition
DOI: https://doi.org/10.1016/j.oneear.2026.101772
Authors: Sang Yup Lee (KAIST, corresponding author), Seok Yeong Jung (KAIST, first author), Sol Choi (SilicoBio, second author), Jun-Woo Kim (SilicoBio and Inha University, third author), and two others
SilicoBio is a KAIST faculty startup founded in June 2025 by Distinguished Professor Sang Yup Lee, a world-renowned scholar in synthetic biology. The company focuses on connecting laboratory-level achievements in systems metabolic engineering to real industrialization. By combining KAIST’s core technologies with the industrialization experience of personnel from CJ BIO, SilicoBio has built a team capable of reviewing not only strain design, but also industrial-scale fermentation and scale-up, material purification and product development, pilot production, and process validation. Based on this foundation, SilicoBio is pursuing a phased commercialization strategy, starting with next-generation protein products and expanding into functional ingredients and eventually new drug and novel material candidates.
This research was supported by the “Development of Next-Generation Biorefinery Core Technologies to Lead the Biochemical Industry” project under the Petroleum-Alternative Eco-Friendly Chemical Technology Development Program funded by the Ministry of Science and ICT, and by the “Advancement of a Synthetic Biology-Based Industrial Cell Factory Platform and Commercialization of High-Value Functional Biomaterials” project under the Deep Science Startup Activation Support Program funded by the Commercialization Promotion Agency for R&D Outcome.
KAIST Brings the Era of Microbial Cell Factories One Step Closer
The era of "biomanufacturing", in which microbes, not petroleum, produce chemical products, is one step closer. A KAIST research team has analyzed the key challenges limiting the commercialization of biomanufacturing and proposed an AI-driven strategy for industrialization.
KAIST (President Choongsik Bae) announced on the 14th of July that a research team led by Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering has comprehensively analyzed the key bottlenecks to commercializing biomanufacturing and proposed an industrialization strategy and a roadmap for future growth to address them.
Most chemical products today — including plastics, textiles, and pharmaceutical raw materials — are produced from petroleum. But as concerns over carbon emissions and environmental pollution grow, biomanufacturing, which uses microbes to produce chemicals, is drawing attention as a next-generation manufacturing technology. Still, scaling up lab-developed technologies into economically viable mass production at actual factories remains a major challenge.
Systems metabolic engineering, a core technology in biomanufacturing, designs and optimizes microbial metabolic pathways to build "microbial cell factories" that produce desired chemicals. But technologies that show high productivity in the lab often perform worse once moved to industrial settings — productivity drops, production costs rise, and many fail to achieve price competitiveness, ultimately failing to commercialize.
The research team analyzed succinic acid, a bio-based chemical feedstock, and polyhydroxyalkanoate (PHA), a biodegradable plastic, as representative cases illustrating this "gap between the lab and industry," often called the "valley of death."
Succinic acid is a key raw material for producing eco-friendly plastics and various chemical materials. The team explained that for succinic acid to compete with existing petrochemical products, competitiveness depends not just on production volume, but also on raw material and separation/purification costs, the fermentation process, and market size — all of which must be weighed together. The team also suggested that a phased strategy — entering high-value markets such as pharmaceuticals, cosmetics, and food ingredients first — could be a realistic solution.
PHA is a biodegradable plastic that microbes accumulate inside their cells, an eco-friendly material that breaks down naturally in the environment after use. But PHA is currently less price-competitive than conventional plastics due to high production and recovery costs, and its intrinsic material properties pose a separate barrier: the archetypal polymer P(3HB) is highly crystalline, becomes brittle with age, and has a narrow window between its melting and decomposition temperatures, meaning PHAs are generally not suitable as direct "drop-in" replacements.The team found that a phased approach is needed — simplifying the production process and first applying it to high-value fields such as medical applications and food packaging before expanding into general-purpose markets.
The team predicted that artificial intelligence will become a key to industrializing biomanufacturing going forward. AI can optimize the entire biomanufacturing process — from enzyme and microbial design to digital twins that virtually simulate production processes, and technologies that simultaneously analyze economic feasibility and environmental impact. The team explained that this can shorten development timelines, reduce production costs, and increase the likelihood of successful commercialization.
The team also proposed that techno-economic analysis (TEA) and life cycle assessment (LCA) should be applied as design criteria from the earliest stages of research, rather than as evaluations conducted only after research is complete. The team further emphasized that supply chain resilience — accounting for raw material availability and shifts in the international landscape — should be considered a new design standard for biomanufacturing.
This study is significant not for developing a new production technology, but for comprehensively analyzing the conditions for successful biomanufacturing industrialization and presenting an industrialization roadmap spanning the entire cycle — from securing raw materials to microbial design, fermentation, separation and purification, and market entry. The team expects the study to accelerate the commercialization of the bio-based chemical industry and, over the long term, contribute to shifting the petroleum-centered chemical industry toward an eco-friendly bioeconomy.
The paper, with Ji Yeon Kim and Hye Eun Yu as co-first authors, both Ph.D. candidates in KAIST's Department of Chemical and Biomolecular Engineering, was published online on May 30 in the international journal Nature Communications.
※ Paper title: Beyond petrochemicals: challenges and opportunities in industrial-scale biomanufacturing
※ DOI: 10.1038/s41467-026-73835-1
※ Authors: Ji Yeon Kim (KAIST, co-first author), Hye Eun Yu (KAIST, co-first author), Min Ho Kim (KAIST), Sang Yup Lee (KAIST, corresponding author)
This research was supported by the National Research Foundation of Korea, funded by the Ministry of Science and ICT, through the “Development of Platform Technologies of Microbial Cell Factories for Next-Generation Biorefineries” project (Project No. 2022M3J5A1056117) and the “Development of Advanced Synthetic Biology Source Technologies for Leading the Biomanufacturing Industry” project (Project No. RS-2024-00399424).